title: Clinicopathological characteristics and her-2/neu status in chinese patients with uterine papillary serous carcinoma.
abstract: Objective. To analyze clinico-pathological features of Chinese patients with UPSC, and investigate roles of Her-2/neu protein expression and gene amplification in UPSC prognosis. Methods. Thirty-six patients with UPSC treated in Cancer Hospital of Fudan University from 1996 to 2006 were analysed retrospectively. Chromogenic in situ hybridization (CISH) and immunohistochemistry (IHC) were performed to evaluate Her-2/neu gene amplification and protein expression respectively. Results. The median age was 63 years, and 61% (22/36) were late stages (stage III/IV). The 1-year, 3-year, and 5-year overall survival (OS) was 73.1%, 51.9% and 43.9%, respectively. Advanced stages (P = .0006) and deep myometrial invasion (P = .0138) were significantly associtated with a shorter OS. In 36 cases, 27.8% (10/36) showed 2+ staining and 8.3% (3/36) showed 3+ by IHC. Amplification of the Her-2/neu gene was observed in 11.1% (4/36) cases. The 5-year overall survival rate in Her-2/neu IHC 2 + ∼3+ and 0 ~ 1+ cases was 12.9% and 68.6% respectively. Her-2/neu protein expression 2 + ∼3+ was significantly associated with advanced surgical stage and worse overall survival (P = .03 and P = .0023, resp.). Conclusion. Chinese patients with UPSC showed characteristics of deep myometrial invasion, advanced stages and poor overall survival. Her-2/neu protein overexpression is associated with advanced stage and poor survival outcome.
authors.affiliation: Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, China.
authors.forename: Yulan
authors.initials: Y
authors.lastname: Ren
authors.forename: Huaying
authors.initials: H
authors.lastname: Wang
authors.forename: Xiaoyan
authors.initials: X
authors.lastname: Zhou
authors.forename: Wentao
authors.initials: W
authors.lastname: Yang
authors.forename: Xiaowei
authors.initials: X
authors.lastname: Huang
authors.forename: Yongming
authors.initials: Y
authors.lastname: Lu
authors.forename: Daren
authors.initials: D
authors.lastname: Shi